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Insulin resistance occurs in 20%–25%of the hu-
man population, and the condition is a chief
component of type 2 diabetes mellitus and
a risk factor for cardiovascular disease and cer-
tain forms of cancer. Herein, we demonstrate
that the sphingolipid ceramide is a common
molecular intermediate linking several different
pathological metabolic stresses (i.e., glucocor-
ticoids and saturated fats, but not unsaturated
fats) to the induction of insulin resistance.More-
over, inhibition of ceramide synthesis markedly
improves glucose tolerance and prevents the
onset of frank diabetes in obese rodents. Col-
lectively, these data have two important impli-
cations. First, they indicate that different fatty
acids induce insulin resistance by distinct
mechanisms discerned by their reliance on
sphingolipid synthesis. Second, they identify
enzymes required for ceramide synthesis as
therapeutic targets for combating insulin resis-
tance caused by nutrient excess or glucocorti-
coid therapy.
INTRODUCTION
The peptide hormone insulin stimulates the uptake and
storage of glucose and other nutrients in skeletal muscle
and adipose tissue while simultaneously repressing glu-
cose efflux from the liver. Insulin resistance occurs when
a normal dose of the hormone is incapable of eliciting
these anabolic responses, and the condition is a compo-
nent of or risk factor for many metabolic diseases (e.g.,
diabetes, hypertension, atherosclerosis, cancer, etc.)
(Reaven, 2005). Obesity predisposes individuals to the de-
velopment of insulin resistance, and several mechanisms
have been proposed to explain how increased adiposityCellantagonizes insulin stimulation of nutrient uptake and stor-
age. First, increased adipose tissue mass may trigger the
synthesis and/or secretion of glucocorticoids (Hermanow-
ski-Vosatka et al., 2005) or inflammatory cytokines (e.g.,
tumor necrosis factor a [TNFa]) (Hotamisligil, 2003) that in-
hibit insulin action in peripheral tissues. Second, excess
lipids may be delivered to nonadipose tissues that are
not suited for fat storage (i.e., skeletal muscle and the
liver), thus leading to the formation of specific metabolites
that directly antagonize insulin action (McGarry, 2002;
Schmitz-Peiffer, 2000).
The metabolic factors that induce insulin resistance al-
most invariably generate the sphingolipid ceramide (Sum-
mers and Nelson, 2005), which is a ubiquitous regulator of
cellular stress (Hannun and Obeid, 2002). Moreover, stud-
ies in insulin-responsive cell types suggest that ceramide
and/or its derivatives (e.g., ganglioside GM3 and sphingo-
sine) antagonize insulin signaling, induce oxidative stress,
and inhibit glucose uptake and storage, and thus may ini-
tiatemany of themolecular defects that underlie insulin re-
sistance (Summers and Nelson, 2005). An exciting theory
that emerges from these observations is that the inhibition
of ceramide synthesis could combat several underlying
causes of insulin resistance and thus improve insulin sen-
sitivity in tissues exposed to multiple different pathogenic
factors associated with obesity. However, studies evalu-
ating the relevance of ceramide to insulin resistance in
vivo have been controversial. The debate stems from the
fact that while ceramide accumulates in some insulin-
resistant models (Gorska et al., 2004; Straczkowski
et al., 2004; Turinsky et al., 1990), it fails to do so in
lipid-infused animals (Itani et al., 2002; Yu et al., 2002).
Moreover, the relative increase in ceramide in obese ro-
dents and humans is typically rather small (Adams et al.,
2004; Turinsky et al., 1990). Thus, some scientists have
argued that it either is unimportant in lipid-induced insulin
resistance or, alternatively, plays only a minor role in the
regulation of glucose homeostasis following nutrient over-
supply (Itani et al., 2002; Yu et al., 2002). To definitively
address this issue, we investigated whether inhibitingMetabolism 5, 167–179, March 2007 ª2007 Elsevier Inc. 167
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Sphingolipids and Insulin ResistanceFigure 1. Ceramide Is a Requisite Intermediate Linking Dexamethasone to Insulin Resistance
(A) Sprague-Dawley rats were pretreated with myriocin (300 mg/kg, i.p.; solid bars) or saline (open bars) prior to administering dexamethasone
(40 mg/kg, i.p.) or vehicle (5% ethanol in PBS). Mean ceramide levels from portal vein serum (n = 9) or nitrogen-pulverized liver (n = 11) are shown.
To directly compare fold changes in ceramide levels within the liver and portal serum, valueswere normalized to those from untreated control samples
(40.42 pmol/ml for serum and 430 pmol/mg for liver). In this and all other figures, error bars represent ±SEM.
(B) Protein (open bar) andmRNA (solid bars) were extracted andmeasured bywestern blotting and reverse-transcriptase PCR, respectively. Levels of
transcripts encoding enzymes required for ceramide synthesis or metabolism are presented as the fold change in transcript or protein in dexameth-
asone-treated animals relative to vehicle controls. SPT2, LASS1, LASS6, GCS, and AC were significantly elevated in the dexamethasone-treated
animals (n = 5).168 Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier Inc.
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Sphingolipids and Insulin Resistanceceramide synthesis improves glucose homeostasis in ro-
dent models of insulin resistance, obesity, and diabetes.
RESULTS
Ceramide Is an Obligate Intermediate Linking
Glucocorticoids to the Induction of Insulin
Resistance
Synthetic glucocorticoids (e.g., dexamethasone), one of
the most frequently prescribed classes of therapeutics,
impair glucose tolerance. This is particularly troublesome
given the large number of insulin-resistant and/or diabetic
individuals receiving these drugs. Though obese individ-
uals do not have elevated glucocorticoid levels in the cir-
culation, increased intracellular glucocorticoid tone—
likely driven by increased activity of 11b-hydroxysteroid
dehydrogenase type 1, which converts inactive cortisone
into active cortisol—causes insulin resistance in rodents
and may contribute to the development of the disease in
humans (Kotelevtsev et al., 1997, 1999; Masuzaki et al.,
2001, 2003). As shown herein, dexamethasone stimulates
ceramide biosynthesis by inducing expression of genes
required for ceramide biosynthesis. The initial and rate-
limiting reaction is the condensation of palmitoyl-CoA
and serine, which is catalyzed by serine palmitoyltransfer-
ase (SPT), to produce 3-oxosphinganine (Merrill, 2002;
see also Figure S1 in the Supplemental Data available
with this article online). Three subsequent reactions follow,
resulting in the production of sphinganine, dihydrocera-
mide, and ultimately ceramide. Once generated, ceramide
is the precursor of most active sphingolipids, including
glucosylceramides, sphingosine, ceramide 1-phosphate,
and sphingomyelin. Dexamethasone promoted ceramide
accumulation in the portal circulation and the liver (Fig-
ure 1A). Moreover, it induced hepatic expression of serine
palmitoyltransferase isoform 2 (SPT2) and (dihydro)cera-
mide synthases (i.e., longevity assurance gene homolog
[LASS] 1 and 6) (Figure 1B). It also promoted expression
of glucosylceramide synthase (GCS) and acid ceramidase
(AC), suggesting that glucocorticoids may additionally in-
crease formation of corresponding inhibitory sphingolipid
metabolites such as ganglioside GM3 and sphingosine.
Concomitant with the increase in ceramide accumula-
tion, dexamethasonemildly increased (13%) fasting blood
glucose (Figure 1C) and induced a2.8-fold increase in fast-
ing insulin concentrations (Figure 1D). Furthermore, dexa-
methasone impaired glucose disposal (Figure 1C) and
elevated insulin levels during the course of a glucose toler-
ance test (Figure 1D), suggestive of insulin resistance. Re-
ducing ceramide levels with the SPT inhibitor myriocinCe(Figure 1A) significantly negated glucocorticoid-induced
glucose intolerance (Figure 1C) and normalized circulating
insulin concentrations following glucose challenge (Fig-
ure 1D).
Insulin tolerance tests suggested that dexamethasone
impaired glucose homeostasis by decreasing insulin sen-
sitivity, and this effect was fully negated by myriocin (Fig-
ure S2). To definitively evaluate effects on insulin sensitiv-
ity, as well as to distinguish whether our treatment
protocols differentially affected glucose uptake in skeletal
muscle or hepatic glucose output by the liver, we per-
formed hyperinsulinemic-euglycemic clamps with
D[U-14C]glucose and 2-deoxy-D[2,6-3H]glucose (2-DOG)
tracers (Figure 1; Table 1). Dexamethasone decreased
the glucose infusion rate required to maintain euglycemia
(Figure 1F), prevented insulin-induced suppression of he-
patic glucose output (Figure 1G), and inhibited 2-DOG up-
take into skeletal muscle (Figure 1H). Pretreatment with
myriocin partially blocked dexamethasone-induced insu-
lin resistance in skeletal muscle and completely prevented
the glucocorticoid’s effects on hepatic glucose output.
Neither dexamethasone nor myriocin affected rates of
basal (non-insulin-stimulated) hepatic glucose output.
We and others have demonstrated previously that ce-
ramide antagonizes insulin stimulation of glucose uptake
and glycogen synthesis by inhibiting phosphorylation
and activation of Akt/protein kinase B (PKB) (Hajduch
et al., 2001; Powell et al., 2003; Stratford et al., 2004; Sum-
mers et al., 1998; Teruel et al., 2001), a central mediator of
insulin’s anabolic effects. In these prior studies, ceramide
failed to inhibit phosphatidylinositol 3-kinase (PI3-kinase),
an obligate intermediate in the signaling pathway linking
insulin to the stimulation of Akt/PKB. We thus tested
whether dexamethasone and myriocin altered the phos-
phorylation of Akt/PKB on serine 473, an important regu-
latory residue in the enzyme’s C terminus. Treating rats
with dexamethasone markedly impaired insulin stimula-
tion of Akt/PKB in the liver without affecting PI3-kinase
(Figure 1E). Myriocin completely negated this dexametha-
sone effect. Myriocin similarly negated dexamethasone
inhibition of Akt/PKB in soleus muscle (Figure S2B). Col-
lectively, these data support the hypothesis that ceramide
inactivation of Akt/PKB is a contributing mechanism by
which the sphingolipid impairs insulin action.
To substantiate the data obtained with myriocin, we
tested whether the genetic ablation of one or both alleles
of dihydroceramide desaturase 1 (Des1) (GenBank acces-
sion number NM_007853), which encodes the enzyme
that converts metabolically inactive dihydroceramide
into active ceramide (Figures S3A and S3B), markedly(C and D) Rats were challenged with glucose (1 g/kg, i.p.) following treatment with dexamethasone (Dex, squares) or ethanol carrier (triangles) and/or
myriocin (open shapes) or saline (solid shapes) as in (A). Tail-vein blood was sampled for glucose (C) and insulin (D) at the indicated times (n = 6).
(E) In animals treated with dexamethasone as above, insulin was injected into the portal vein as described previously (Pagliassotti et al., 2002). Livers
were freeze clamped in situ, and PI3-kinase assays and western blots to detect phosphorylated (at serine 473) and total Akt/PKB were performed as
described in Experimental Procedures. Data are representative of six different independent experiments.
(F–H) Hyperinsulinemic-euglycemic clamps were performed on animals (n = 9 for myriocin-treated controls, n = 6 for other groups) treated as in (A)
with myriocin (solid bars) or PBS (open bars). *p < 0.05 for dexamethasone-treated animals versus PBS-treated controls; yp < 0.05 for animals re-
ceiving myriocin + dexamethasone versus those receiving dexamethasone + vehicle. When comparing glucose and insulin levels during the glucose
tolerance test, significance was determined using the area under the curve.ll Metabolism 5, 167–179, March 2007 ª2007 Elsevier Inc. 169
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Sphingolipids and Insulin ResistanceTable 1. Plasma Components during Hyperinsulinemic-Euglycemic Clamp Studies
Dexamethasone Clamps
Treatment Before Clamp During Clamp
Dexamethasone Myriocin Glucose (mg/dl) Insulin (ng/ml) FFA (mmol/l) Glucose (mg/dl) Insulin (ng/ml)
Control Saline 121.2 ± 5.4 1.12 ± 0.32 240 ± 27 129.2 ± 2.8 5.8 ± 0.9
Myriocin 113.0 ± 5.3 1.09 ± 0.18 258 ± 29 128.3 ± 2.1 6.4 ± 0.4
Dexamethasone Saline 145.6 ± 5.3* 4.50 ± 1.76 211 ± 38 132.2 ± 3.4 6.8 ± 1.1
Myriocin 134.6 ± 2.7* 2.34 ± 0.44 176 ± 34 127.4 ± 2.9 5.7 ± 1.4
Lipid Infusion Clamps
Treatment Glucose (mg/dl) Insulin (ng/ml) FFA (mM)
Lipid Drug
Before
Infusion
Before
Clamp
During
Clamp
Before
Infusion
Before
Clamp
During
Clamp
Before
Infusion
Before
Clamp
During
Clamp
Glycerol PBS 123.9 ± 6.9 113.9 ± 2.4 114.3 ± 3.6 0.59 ± 0.16 1.33 ± 0.32 5.66 ± 1.07 0.55 ± 0.06 0.52 ± 0.04 0.23 ± 0.05a
Myriocin 108.6 ± 3.8 114.5 ± 4.4 110.4 ± 3.9 0.52 ± 0.08 1.30 ± 0.30 5.09 ± 0.52 0.71 ± 0.08 0.48 ± 0.03 0.28 ± 0.03a
Lard oil PBS 120.8 ± 5.0 110.4 ± 5.2 121.0 ± 5.0 0.82 ± 0.09 1.69 ± 0.24 5.71 ± 0.94 0.61 ± 0.11 1.89 ± 0.05* 1.57 ± 0.15*
Myriocin 98.2 ± 6.6* 105.5 ± 5.0 122.5 ± 0.9 0.62 ± 0.09 2.00 ± 0.53 4.73 ± 0.88 0.76 ± 0.20 2.12 ± 0.32* 1.87 ± 0.29*
Soy oil PBS 116.4 ± 10.7 116.2 ± 4.8 121.6 ± 4.9 0.97 ± 0.03 1.94 ± 0.40 6.00 ± 1.24 0.52 ± 0.07 2.24 ± 0.40* 1.59 ± 0.36*
Myriocin 104.0 ± 9.2 102.6 ± 4.0 124.8 ± 2.7* 0.60 ± 0.08y 2.04 ± 0.49 5.91 ± 0.54 0.67 ± 0.09 2.25 ± 0.13* 1.72 ± 0.26*
Dexamethasone clamps: Plasma parameters were assessed during hyperinsulinemic-euglycemic clamps of dexamethasone-
treated Sprague-Dawley rats. Plasma was sampled from indwelling arterial lines before the infusion of insulin or during a 60 min
euglycemic steady state. Glucose was analyzed using a Beckman Glucose Analyzer II approximately every 7 minutes throughout
the steady-state period. Insulin was analyzed by ELISA from two steady-state samples. Free fatty acid (FFA) was measured using
the colorimetric half-micro test from Roche. (n = 9 for myriocin-treated animals; n = 6 for other groups.) *p < 0.05 versus saline-
injected controls. Lipid infusion clamps: Plasma parameters were assessed during hyperinsulinemic-euglycemic clamps of lipid-
infused Sprague-Dawley rats. Plasma was sampled from indwelling arterial lines before the infusion of lipid, before coinfusion of
insulin, or during a 30 min euglycemic steady state. Glucose was analyzed using a Beckman Glucose Analyzer II approximately
every 5 minutes throughout the steady-state period. Insulin was analyzed by ELISA from terminal plasma samples. FFA was mea-
sured using the colorimetric half-micro test fromRoche. *p < 0.05 versus PBS-treated, glycerol-infused controls (n = 6); yp < 0.05 for
animals receiving myriocin versus vehicle-treated animals undergoing an otherwise identical treatment regimen (n = 6).
a FFA levels obtained during the clamp were significantly different from those found just prior to initiating the clamp.altered tissue sphingolipid levels and glucose homeosta-
sis. Homozygous null (Des1/) pups contained no de-
tectable DES1 protein and much less ceramide, but dra-
matically more dihydroceramide (Figure 2B), than wild-
type (Des1+/+) or heterozygous (Des1+/) littermates.
Moreover, heart, liver, pancreas, white adipose tissue
(WAT), and soleus muscle obtained from 7-week-old
Des1/ animals contained no detectable ceramide levels
(n = 3; p < 0.01), while those dissected from Des1+/ mice
had a markedly reduced ratio of active ceramide to inac-
tive dihydroceramide (Figure 2C).
The homozygous null Des1/mice revealed an incom-
pletely penetrant lethality (Figure S3C). Surviving animals
were small in size (Figure S4B) with a complex phenotype,
including scaly skin and sparse hair (Figure 2A), tremors,
and numerous blood chemistry and hematological abnor-
malities. The homozygous null mice also exhibited signs of
growth retardation when compared with their wild-type lit-
termates, including notably decreased mean body weight
and length, total tissue mass, lean body mass, and bone
mineral content and density measurements. In addition,
these mutants exhibited abnormal liver function test re-
sults, including increased mean serum alkaline phospha-
tase, alanine aminotransferase, and total bilirubin levels.170 Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier InThe animals ultimately failed to thrive, dying within 8 to
10 weeks of birth. The heterozygous Des1+/ animals
were born at Mendelian ratios and demonstrated no obvi-
ous health abnormalities. Although ceramide has been im-
plicated in immune cell function, neither the Des1/ nor
Des1+/ animals displayed alterations in circulating white
blood cells, lymphocytes, or neutrophils (data not shown).
Because of the sickly nature of the homozygous null
Des1/ mice, we restricted our analysis of glucose me-
tabolism to the heterozygous Des1+/ animals. When
compared to wild-type Des1+/+ littermates, the Des1+/
animals had normal glucose tolerance (data not shown)
but demonstrated enhanced insulin sensitivity (Figures
2D and 2E). Moreover, they were refractory to dexameth-
asone-induced insulin resistance (Figures 2D and 2E).
These studies strongly support the conclusion that ceram-
ide synthesis is requisite for glucocorticoid-induced insu-
lin resistance.
Distinct Mechanisms for Saturated-
and Unsaturated-Fat-Induced Insulin Resistance
An additional mechanism bywhich insulin resistance likely
develops in theobese is through theaccumulation of fats in
tissues not suited for lipid storage (McGarry, 2002). Toc.
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Sphingolipids and Insulin ResistanceFigure 2. Mice Lacking Dihydroceramide Desaturase 1 (DES1) Are Resistant to Dexamethasone-Induced Insulin Resistance
(A) Mice lacking DES1 were generated as described in Experimental Procedures. Mice lacking one allele (Des1+/) were indistinguishable from
wild-type (Des1+/+) animals, while those lacking both alleles (Des1/) had a markedly different phenotype described in the text.
(B) Whole-body ceramide and dihydroceramide were quantified by mass spectrometry from 1-day-old Des1+/+ (open bars), Des1+/ (solid bars), or
Des1/ (hatched bars) mice (n = 5).
(C) Ceramide and dihydroceramide were quantified by mass spectrometry from individual tissues isolated from 7-week-old Des1+/+ (open bars) or
Des1+/ (solid bars) mice (n = 5).
(D) Fasting insulin resistance indices were calculated frommice treated for 1 week with dexamethasone (Dex, 2 mg/kg/day, i.p.; solid bars) or vehicle
(open bars) (n = 4). Differences were assessed by comparing total area under the curve.
(E) Insulin tolerance tests were initiated by injection of insulin (0.75 mU/kg, i.p.) into Des1+/+ (squares) or Des1+/ (triangles) mice treated with dexa-
methasone (2 mg/kg/day, 10 days; dashed lines, filled shapes) or PBS (solid lines, open shapes). Data are presented as the mean glucose level nor-
malized to the fasting glucose concentration (n = 5). *p < 0.05 versus wild-type littermates; yp < 0.05 for heterozygous mice receiving dexamethasone
versus wild-type animals undergoing the same treatment regimen.Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier Inc. 171
Cell Metabolism
Sphingolipids and Insulin ResistanceFigure 3. Ceramide Is Requisite for Lard-Oil- but Not Soy-Oil-Induced Insulin Resistance
Glycerol (hatched bars), lard oil (solid bars), or soy oil (open bars) was intravenously infused in rats for 6 hr in the presence or absence of myriocin
(MYR).
(A–C) Hyperinsulinemic-euglycemic clamps were initiated after 4.5 hr of infusion, and the mean glucose infusion rate, hepatic glucose output, and
2-deoxyglucose (2-DOG) uptake were quantified as described in Experimental Procedures (n = 6).
(D) Lipid-infused animals were stimulated with insulin (10 mU/kg/min) under euglycemic conditions. Following 30 min of insulin coinfusion, rats were
anesthetized with pentobarbital, and soleus muscles were freeze clamped in situ. Phosphorylation of Akt/PKB was assessed by western blot using
phosphospecific antibodies recognizing the activating serine 473 site. Values were normalized to total Akt/PKB protein present in the lysates, which
was unchanged by any of the treatment protocols. Data are presented as normalized to glycerol controls (n = 6).
(E and F) Ceramide (E) and diacylglycerol (DAG, F) levels in soleus muscles undergoing the treatment protocol described in (D) were quantified as
described previously (Chavez et al., 2003) (n = 6). *p < 0.05 versus control animals infused with glycerol + vehicle; yp < 0.05 for myriocin-infused
animals versus vehicle-treated animals undergoing an otherwise identical treatment regimen.mimic this condition in rats, we delivered a 20% lard-oil/
heparin infusate into the bloodstream of Sprague-Dawley
rats via jugular catheters. As compared to a 2.5% glycerol
infusate, lard-oil infusion increased serum free fatty acid
(FFA) concentrations (Table 1) and promoted ceramide ac-
crual in skeletal muscle (Figure 3E) and liver (249 ± 29
pmol/mg for glycerol versus 401 ± 72 pmol/mg for lard
oil; n = 9; p< 0.05). It also stimulated formation of diacylgly-
cerol (DAG), a glycerolipid previously implicated in lipid-
induced insulin resistance (Figure 3F) (Yu et al., 2002).
To assessmuscle insulin sensitivity during the infusion, hy-
perinsulinemic-euglycemic clamps were performed on172 Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier Incconscious, unrestrained rats during the terminal 90 min
of the protocol. Lard-oil infusion decreased the glucose
infusion rate required to maintain euglycemia to 19% of
glycerol-treated control subjects (Figure 3A), increased
hepatic glucose output (Figure 3B), and inhibited whole-
body 2-DOG uptake (Figure 3C). Moreover, it inhibited
insulin stimulation of Akt/PKB (Figure 3D). However, the in-
clusion of myriocin, which blocked ceramide synthesis in
soleus muscle (Figure 3E) and liver (118 ± 38 pmol/mg for
lard oil; n = 6; p < 0.05 versus vehicle control), negated
these lard-oil effects (Figures 3A–3C). Differences in the
glucose infusion rate could not be accounted for by the.
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Sphingolipids and Insulin Resistanceslight differences in the glucose concentration that were
achieved during the clamp or differences in steady-state
insulin or fatty-acid concentrations (Table 1). Neither lard
oil nor myriocin affected rates of basal (non-insulin-
stimulated) hepatic glucose output. Myriocin did not
reduce levels of DAG (Figure 3F), indicating that ceramide,
and not DAG, is the primary regulator of insulin resistance
induced by this lard-oil cocktail. Moreover, myriocin failed
to prevent lipid induction of TNFa and interleukin-6, two
inflammatory cytokines previously implicated in lipid
induction of insulin resistance. Thus, myriocin works either
independently or downstream of these inflammatory
modulators.
Many studies investigating acute effects of lipids on in-
sulin action have involved the infusion of Intralipid or Lip-
osyn II (Boden and Shulman, 2002; Kim et al., 2004; Kim
et al., 2001; Kim et al., 2002; Yu et al., 2002), which are
soy-based lipid cocktails enriched in the unsaturated fat
linoleate but low in the saturated fatty acids required for
synthesis of the sphingosine backbone of ceramide (Cha-
vez and Summers, 2003). As shown previously, soy-oil
(i.e., Intralipid) infusion decreased the glucose infusion
rate required to maintain euglycemia and inhibited
whole-body 2-DOGuptake (Figures 3A and 3C) without in-
ducing ceramide accumulation (Yu et al., 2002) (Figure 3F).
Like lard oil, however, it markedly elevated circulating
FFAs (Table 1), inhibited insulin stimulation of Akt/PKB
(Figure 3D), and increased muscle DAG levels (Figure 3F).
Myriocin did not prevent Intralipid-induced DAG accumu-
lation (Figure 3E) or insulin resistance (Figures 3A, 3C, and
3D), confirming that soy-based cocktails induce insulin
resistance in muscle by a ceramide-independent mecha-
nism. Although the soy-oil infusion failed to induce ceram-
ide, myriocin treatment alone decreased hepatic ceram-
ide levels to 27% of saline-treated controls. Interestingly,
this reduction in liver ceramide partially restored insulin
suppression of hepatic glucose output.
The differential sensitivity of the lard- and soy-oil emul-
sions to inhibitors of ceramide synthesis suggests that dif-
ferent fatty acids may induce insulin resistance in muscle
by distinct mechanisms. To test this hypothesis, we eval-
uated whether insulin resistance induced by saturated
(palmitate) or unsaturated (linoleate) FFAs, which differ in
abundance in the cocktails and in their capacity to gener-
ate ceramide, demonstrated a differential sensitivity to in-
hibitors of ceramide synthesis. Following completion of
a 6 hr incubation, both palmitate and linoleate inhibited in-
sulin-stimulated 2-DOG uptake (Figure 4C) and induced
DAG accrual (Figure 4B) in isolated muscle strips. How-
ever, palmitate, but not linoleate, promoted ceramide ac-
cumulation (Figure 4A). To ascertain whether ceramide se-
lectively mediated the antagonistic effects of palmitate,
identical groups of muscles were treated with myriocin
(10 mM) or cycloserine (1 mM), a structurally unrelated in-
hibitor of serine palmitoyltransferase. Both compounds
prevented palmitate-induced ceramide accumulation
without affecting DAG (Figures 4A and 4B), and the inclu-
sion of either drug completely negated the antagonistic ef-
fects of palmitate on insulin-stimulated 2-DOG uptakeCell(Figure 4C). By contrast, these compounds did not alter li-
noleate effects on DAG accumulation (Figure 4B) or 2-
DOG uptake (Figure 4C). Results obtained using muscles
isolated from the aforementioned knockout mice further
supported the hypothesis, as the Des1+/ animals were
resistant to palmitate antagonism of 2-DOG uptake but
were fully inhibited by linoleate (Figure 4D).
Inhibiting Ceramide Synthesis Improves Glucose
Tolerance and Prevents Diabetes in Obese Rodents
We next asked whether modulating ceramide levels could
be an effective therapeutic strategy for combating insulin
resistance and glucose intolerance in rodent models of
obesity. Zucker diabetic fatty (ZDF) rats, which become
diabetic at 10–11 weeks of age, and lean controls were
givenmyriocin for up to 6weeks. As in prior studies (Hojjati
et al., 2005; Park et al., 2004), the compound was well tol-
erated, as it had no effect on body mass (Figure S5A) or
epididymal fat mass (Figure S5B) and no apparent side ef-
fects. As predicted, animals treated with vehicle demon-
strated a progressive increase in plasma glucose (Fig-
ure 5A) and triglycerides (Figure 5B). Moreover, these
animals failed to maintain the compensatory hyperinsuli-
nemia seen in early stages of glucose intolerance, and
the disease progressed as circulating insulin levels fell
(Figure 5C). Treatment with myriocin, starting at week 8,
prevented the onset of diabetes, as evidenced by the re-
duced glucose and triglyceride levels in the drug-treated
animals (Figures 5A and 5B). The improvement in blood
glucose levels persisted until the animals were at least
16 weeks in age (data not shown). Ceramides were ele-
vated in soleus muscle (Figure 5D), liver (Figure 5E), and
serum (Figure 5F) of the ZDF rats, and myriocin reduced
levels of the sphingolipid in all of these tissues. Myriocin
improved glucose tolerance and lowered insulin levels in
the ZDF rats (Figures 6A and 6B) and improved insulin
sensitivity as measured by insulin tolerance tests
(Figure 6C). Zucker fa/fa rats (Figure S6) also showed im-
provement in glucose tolerance when treated with myrio-
cin. Similarly, myriocin reduced insulin levels after glucose
challenge in diet-induced obesemice with normal glucose
tolerance (Figure S7), which suggests improved insulin
sensitivity. Collectively, these data identify ceramide
synthesis inhibition as a therapeutic strategy for combat-
ing insulin resistance associated with excessive nutrient
intake.
DISCUSSION
A collision of genetic and environmental factors has
produced an epidemic growth of obesity and insulin-
resistance rates during the last decade. As a result, prog-
nosticators estimate that life expectancy, which has risen
steadily over the last two centuries, may soon start to de-
cline (Olshansky et al., 2005). In humans, the development
of insulin resistance is likely caused by a diverse range of
factors (nutrients, inflammatory cytokines, and glucocorti-
coids) that are influenced by obesity and a sedentary life-
style. Ceramide is a candidate molecular intermediateMetabolism 5, 167–179, March 2007 ª2007 Elsevier Inc. 173
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Sphingolipids and Insulin ResistanceFigure 4. Ceramide Is Essential for Palmitate- but Not Linole-
ate-Induced Insulin Resistance
(A–C) Soleus muscles were isolated, bisected, and placed in oxygen-
ated Krebs-Henseleit buffer containing 2.5% FFA free bovine serum
albumin (BSA, hatched bars), 1 mM palmitate (solid bars), or 1 mM
linoleate (open bars). Indicated muscle strips were maintained in the
presence of cycloserine (CS, 1 mM) or myriocin (MYR, 10 mM) through-
out the experiments. Ceramide (A) and DAG (B) were enzymatically
quantified, and data were normalized to the BSA-treated muscle strip
from the same rat. 2-DOG uptake (C) was measured as previously de-
scribed (Brozinick and Birnbaum, 1998) in the absence (open bars) or
presence of insulin (300 mU/ml; solid bars) during the final 20 min of the
6 hr incubation.
(D) Intact soleus muscles were dissected from 15- to 20-week-old
Des1+/ and Des1+/+ mice and incubated for 6 hr in lipid (1 mM) as174 Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier Inlinking many of these metabolic stresses to the induction
of insulin resistance (Summers and Nelson, 2005), and
the sphingolipid accumulates in insulin-resistant humans
(Adams et al., 2004). Herein, we demonstrate that ceram-
ide synthesis is an important component of insulin resis-
tance triggered by at least two different pathogenic insults
(i.e., glucocorticoids and saturated fatty acids). Moreover,
inhibition of ceramide biosynthesis markedly improved
glucose homeostasis in rodent models of obesity and di-
abetes. Thus, excess accumulation of ceramide and/or
its metabolites likely underlies the antagonism of insulin
signaling that leads to insulin resistance.
The studies presented have additional implications to-
ward our understanding of the pathology of insulin resis-
tance caused by lipid oversupply. Findings obtained using
lipid-infusion protocols have suggested that DAG, and not
ceramide, is the primary mediator of lipid-induced insulin
resistance (Itani et al., 2002; Yu et al., 2002). We can ex-
plain differences between our study and previous ones
by demonstrating that ceramide synthesis is dispensable
for insulin resistance caused by unsaturated fats (e.g., li-
noleate), which do not drive ceramide synthesis. By con-
trast, ceramide is a requisite intermediate linking satu-
rated fatty acids (i.e., palmitate) to the antagonism of
insulin action. Thus, these findings provide definitive evi-
dence that different fatty acids antagonize insulin-stimu-
lated glucose uptake by distinct mechanisms discerned
by their intracellular routes of metabolism and that prior
studies relying on lipid cocktails comprised predominantly
of unsaturated fatty acids may have underappreciated the
roles of ceramides in insulin resistance. Since both dietary
and epidemiological studies strongly implicate saturated
fats, which are more poorly oxidized than unsaturated
fats (Gaster et al., 2005), in the induction of human insulin
resistance (Rivellese and Lilli, 2003), modulators of ceram-
ide may prove useful for combating insulin resistance
caused by oversupply of saturated fats. Supporting this
conclusion are studies in rodents and humans indicating
that ceramide inversely correlates with insulin sensitivity
(Adams et al., 2004; Straczkowski et al., 2004) and that
exercise decreases ceramide in concert with its beneficial
effects on insulin action (Dobrzyn et al., 2004; Helge et al.,
2004).
Our findings identify both the liver and skeletal muscle
as targets of ceramide-induced insulin resistance. Sur-
prisingly, however, we observed that dexamethasone in-
duced a striking increase in ceramide within the portal
vein. This curious observation suggests that circulating
indicated. During the final hour of the incubation, muscles were treated
with or without insulin (300 mU/ml). 2-DOG uptake was assessed as in
(C). *p < 0.05 versus BSA-treated controls (n = 6); yp < 0.05 for muscles
receiving myriocin or cycloserine versus vehicle-treated muscles un-
dergoing an otherwise identical treatment regimen (n = 6); zp < 0.05
for muscles from Des1+/ animals versus muscles from Des1+/+ ani-
mals undergoing an otherwise identical treatment regimen (n = 6).
Note: for 2-DOG uptake experiments, statistical comparisons were
made only for insulin-treated samples. 2-DOG uptake rates in muscles
not receiving insulin are included for reference purposes.c.
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Homeostasis and Prevents Diabetes in
ZDF Rats
(A–C) Myriocin administered via either oral ga-
vage (0.5 mg/kg/day) or intraperitoneal injec-
tion (0.3 mg/kg every other day, i.p.) markedly
improved glucose homeostasis in male ZDF
rats. Seven-week-old animals were assigned
to vehicle (1% w/v carboxymethylcellulose,
0.25% Tween 80; open bars) or myriocin (oral
gavage; solid bars) groups based on starting
plasma glucose levels and body weight. Blood
samples were obtained 1 hr postdose at the
indicated days from the tail vein of conscious
animals by gentle massage following tail snip.
Plasma was used for measurements of glu-
cose (A), triglyceride (B), and insulin levels (C)
(n = 5).
(D–F) Ceramide was measured enzymatically
from soleus muscle (D), liver (E), or serum (F)
of lean or obese ZDF rats following treatment
with myriocin (0.3 mg/kg every other day, i.p.;
solid bars) or saline (open bars) from age 7
weeks through 15 weeks. yp < 0.05 for myrio-
cin-treated animals versus vehicle-treated ani-
mals undergoing an otherwise identical treat-
ment regimen; *p < 0.05 versus lean controls
(n = 4).ceramide, rather than ceramide derived from endogenous
lipid stores, may be an important modulator of insulin sen-
sitivity in the liver. One hypothesis is that ceramide gener-
ated in and secreted from visceral WAT modulates insulin
sensitivity and glucose output from the liver as a mecha-
nism for communicating nutrient status or energy need.
For example, during periods of acute stress, glucocorti-
coids might trigger the synthesis and secretion of ceram-
ide from WAT, which would decrease hepatic insulin sen-
sitivity and increase the amount of glucose available for
glycolysis. In obese states, increased nutrient load cou-
pled with WAT inflammation would greatly augment ce-
ramide synthesis in WAT, which could contribute to the
sustained insulin resistance that underlies the metabolic
syndrome. In this scenario, ceramide synthesis in other
tissues (e.g., skeletal muscle, vascular endothelial cells,
pancreatic b cells, etc.) may underlie pathogenic re-
sponses to hyperlipidemia but not be a factor in early
stages of obesity-induced glucose intolerance. Elucida-
tion of this mechanism will require novel experimental
strategies to ablate ceramide synthesis in a tissue-specific
manner.
Studies in cultured cells suggest that the primary mech-
anism by which ceramide antagonizes insulin action isCellthrough the inhibition of Akt/PKB (Chavez et al., 2003,
2005; Hajduch et al., 2001; Powell et al., 2003, 2004; Sum-
mers et al., 1998; Teruel et al., 2001; Wang et al., 1998).
Data presented herein are consistent with this mecha-
nism, as ceramide depletion restored signaling to Akt/
PKB in both dexamethasone- and lard-infused animals.
Ceramide appears to block Akt/PKB activation through
two independent pathways. First, ceramide catalyzes
the dephosphorylation of Akt/PKB by activating protein
phosphatase 2A (Chavez et al., 2003; Stratford et al.,
2004; Teruel et al., 2001). Second, ceramide blocks Akt/
PKB translocation to the plasma membrane (Stratford
et al., 2001). Studies by the Hundal laboratory reveal that
protein kinase Cz, which is also activated by ceramide,
may intermediate this ceramide effect by phosphorylating
Akt/PKB on an inhibitory residue within the enzyme’s
pleckstrin homology domain, thus preventing its interac-
tions with 30-phosphoinositides (Powell et al., 2003, 2004).
The ceramide-independent mechanism by which un-
saturated fatty acids (e.g., linoleate) antagonize insulin
signaling remains less clear. DAG has been proposed to
mediate the effects of this lipid cocktail (Yu et al., 2002),
by activating PKCq, which phosphorylates and inactivates
IRS-1 (Kim et al., 2004). However, we have demonstratedMetabolism 5, 167–179, March 2007 ª2007 Elsevier Inc. 175
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incubating cells or isolated muscles (Figure 3) in palmitate
is insufficient to inhibit insulin signaling. One possible ex-
planation for this discrepancy is that DAG comprised of
the linoleate acyl chain (18:2) is a more potent activator
of this pathway than DAG derived from saturated fats. In-
deed, Wakelam (1998) described numerous experimental
Figure 6. Myriocin Improves Glucose Tolerance in ZDF Rats
Seven-week-old male ZDF (squares) and lean (triangles) rats were
dosed with myriocin (300 mg/kg in saline; open symbols) or saline
(closed symbols) every other day.
(A and B) Following 10 days of myriocin treatment, overnight-fasted
rats were challenged with an oral dose of glucose (2.5 g/kg, oral ga-
vage). Glucosewasmeasured by glucometer on whole-blood samples
obtained from a tail nick. Serum was collected at the indicated time
points, and insulin was measured by ELISA (n = 4).
(C) Insulin tolerance tests were initiated by insulin injection (2 U/kg, i.p.)
following an overnight fast in 11-week-old nondiabetic ZDF rats. Glu-
cose injections were given after 15 min to lean controls to rescue
from hypoglycemia. Data are presented as the mean glucose normal-
ized to initial glucose. (n = 4). *p < 0.05 versus lean animals; yp < 0.05
for myriocin-treated samples versus vehicle-treated animals undergo-
ing the same treatment regimen.176 Cell Metabolism 5, 167–179, March 2007 ª2007 Elsevier Infindings supporting the hypothesis that polyunsaturated
forms of DAG, and not saturated derivatives, serve as in-
tracellular signals.
In summary, using an array of pharmacological and ge-
netic tools to modulate ceramide levels in rodents, we
have demonstrated the following herein: first, ceramide
is a common molecular intermediate linking both gluco-
corticoids and saturated fatty acids to the induction of in-
sulin resistance; second, different fatty-acid classes an-
tagonize insulin-stimulated glucose uptake by distinct
mechanisms distinguished by their dependence upon ce-
ramide synthesis; and third, manipulating ceramide levels
in obese rodents ameliorates insulin resistance and blocks
the onset of diabetes. Collectively, these studies identify
enzymes involved in ceramide biosynthesis as therapeutic
targets for combating insulin resistance caused by gluco-
corticoid therapy or obesity.
EXPERIMENTAL PROCEDURES
Animal Surgery
For lipid infusion and hyperinsulinemic-euglycemic clamp protocols,
animals were anesthetized with ketamine (65 mg/kg) and xylazine
(10 mg/kg), and polyethylene catheters were aseptically placed in
the left carotid artery (advanced to the aortic arch) or the right jugular
vein. Catheters were filled with 3% heparinized saline to maintain pa-
tency and exteriorized in the intrascapular region. Buprenorphine (0.03
mg/kg, s.c.) was postsurgically administered for pain control, and an-
imals were allowed to recover (5–7 days) to preoperative weight prior
to experiments.
Hyperinsulinemic-Euglycemic Clamps
Clamps were performed in conscious unrestrained animals using
swivels and tethers (Instech) to allow uninterrupted movement of the
animals without disruption of infusion lines. Hyperinsulinemia was ini-
tiated by intravenous infusion of insulin (4mU/kg/min). Bloodwas sam-
pled from arterial lines at 7 min intervals and analyzed with a Beckman
Glucose Analyzer II (BeckmanCoulter). Euglycemia wasmaintained by
variable infusion of 20% dextrose. Steady state was achieved approx-
imately 90 min after initiating hyperinsulinemia and maintained for at
least 45 min. Glucose infusion rates were calculated as the average
glucose infusion rate during the steady-state period. Additional blood
sampleswere taken before initiating hyperinsulinemia and at the end of
the clamp for analysis of insulin and free fatty acids. [14C]glucose and
[3H]2-DOGwere given as a bolus during the steady-state period for es-
timation of hepatic glucose output and 2-DOG uptake, as previously
described (Ye et al., 2001). Somatostatin (1.2 mg/kg/min) was coadmi-
nistered with insulin in lipid-infused animals to prevent secretion of en-
dogenous glucose in lard-oil-infused rats.
DES1 Knockout Mice
Mouse embryonic stem (ES) cells carrying a mutation in the Des1
gene (accession number NM_007853) were obtained from
OmniBank, a library of gene-trapped ES cell clones identified by a cor-
responding OmniBank sequence tag (OST) (Zambrowicz et al., 1998).
The ES cell clone corresponding to OST 368559, matching the mouse
Des1 sequence, was thawed and expanded. Inverse genomic PCR
analysis of DNA from this clone confirmed the insertion of the gene-
trapping retroviral vector in the first intron of the Des1 gene on chro-
mosome 1, downstream of the translation initiation codon, thus dis-
rupting production of wild-type transcripts. OST 368559 cells were
used to generate mice heterozygous for the Des1 mutation. Geno-
typing was performed using oligonucleotide primers (LTR2, forward:
50-AAATGGCGTTACTTAAGCTAGCTTGC-30; gene-specific primer,c.
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ployed in a multiplex reaction to amplify mutant Des1 alleles.
Lipid Infusion
Male Sprague-Dawley rats (250 grams) were randomly divided into
six different groups. Glycerol, 20% lard-oil, or 20% soy-oil emulsions
were prepared as previously described (Stein et al., 1997) and infused
at a constant rate of 5 ml/kg/hr. To activate lipoprotein lipase, heparin
(6 U/hr) was added to the triglyceride emulsions. Lipids were infused in
animals treated with control injections (normal saline) or myriocin
(100 mg/kg, i.p.). Drugs were given 12 hr prior to lipid infusion, and
equivalent doses were given intravenously at the time of infusion.
Hyperinsulinemic-euglycemic clamps were initiated after 4.5 hr of lipid
infusion by intravenous coinfusion of insulin for the duration of the pro-
cedure. Following lipid infusion, animals were deeply anesthetizedwith
sodium pentobarbital, and soleus muscles and liver were rapidly dis-
sected out and frozen in liquid nitrogen.
Isolated Muscles
Palmitate or linoleate was first dissolved in ethanol (200 mM), and eth-
anol or free fatty acids were conjugated to bovine serum albumin (BSA)
by diluting 1:25 in Krebs-Henseleit buffer (KHB) supplemented with
20% BSA and heating (55C for 30 min, with occasional vortexing).
The final incubation medium was prepared by diluting the conjugated
BSA solution 1:8 in freshly oxygenated KHB. Male Sprague-Dawley
rats (150–200 grams) were deeply anesthetized with sodium pentobar-
bital (110 mg/kg, i.p.), and soleus muscles were isolated, laterally bi-
sected, and transferred to 25 ml Erlenmeyer flasks containing 2 ml of
KHB supplemented with 2.5% BSA, 8 mM glucose, and 1 mM HEPES
(pH 7.2). Muscles were maintained in a shaking water bath at 29C
while being continuously gassed with 95% O2/5% CO2. Following
this incubation, muscles were rapidly frozen in liquid nitrogen or stim-
ulated with insulin (300 mU) for 60 min, and the incorporation of [3H]2-
DOG was assessed during the final 20 min of the incubation using
methods described previously (Brozinick and Birnbaum, 1998). Free
fatty acids were present throughout the glucose uptake assay.
Zucker Diabetic Fatty Rats
Male ZDF rats were obtained from Charles River/Genetic Models, Inc.
at 6 weeks of age. After a 2 week acclimation period, rats were pre-
bled (100 ml) and assigned to vehicle (1% w/v carboxymethylcellu-
lose, 0.25% Tween 80) or myriocin (0.5 mg/kg/day) groups based on
starting plasma glucose levels and body weight (day 1). Rats were
administered compound daily by oral gavage between 8:30 and 9:30
am for 7 days. Blood samples were obtained 1 hr postdose at the in-
dicated days from the tail vein of conscious animals by gentle massage
following tail snip. Blood was collected in EDTA tubes and kept chilled
on ice. Following centrifugation of blood samples, plasmawas used for
measurements of glucose, insulin, and triglyceride levels. In a repeat
analysis, ceramide was measured following treatment with myriocin
(0.3 mg/kg every other day, i.p.) from 8 to 16 weeks of age.
Analysis of Metabolites
Insulin wasmeasured by enzyme-linked immunosorbent assay (ELISA)
using commercially available kits. For ZDF rats, plasma analytes were
measured using a Hitachi 911 clinical chemistry analyzer (Roche). Free
fatty acids were analyzed using a Free Fatty Acids Half-Micro Test Kit
(Roche). Rat ceramide and diacylglycerol were enzymatically quanti-
fied as described previously (Chavez et al., 2003). Mouse ceramides
were measured using mass spectrometry by the Lipidomics Core Fa-
cility at the Medical University of South Carolina. SPT2 protein was de-
tected by immunoblotting with an antibody from Cayman Chemicals
and quantified on a Kodak Image Station 2000R.
Quantitative Real-Time PCR
Total RNAwas extracted and purified from tissues using TRIzol reagent
(Invitrogen) according to the manufacturer’s recommendations. Ex-
tracted RNA was solubilized in FORMAzol and stored at 80C untilCelluse. cDNA was synthesized from the mRNA by reverse-transcriptase
PCR using a commercial cDNA synthesis kit with oligo(dT) primers
(Promega). Quantitative real-time PCR was performed with SYBR
Green Supermix (Bio-Rad) using a Bio-Rad iCycler system. Specific
primer sequences are listed in Table S1. PCR efficiency was examined
by serially diluting the template cDNA, and amelt curve was performed
at the end of each reaction to verify PCR product specificity. A sample
containing no cDNA was used as a negative control to verify the ab-
sence of primer dimers. b-actin reactions were performed side by
side with every sample analyzed. Changes in mRNA level of each
gene for each treatment were normalized to that of the b-actin mRNA
according to Pfaffl (2001). Ceramide synthase primers used to quantify
mRNA levels were previously described (Riebeling et al., 2003).
Protein Analysis
Tissue extracts were resolved by SDS-PAGE, transferred to nitro-
cellulose, and immunoblotted using methods described previously
(Brozinick and Birnbaum, 1998). Detection was performed using the
Enhanced Chemiluminescence Plus kit from Amersham Biosciences
according to the manufacturer’s instructions. Rabbit polyclonal
antibodies recognizing DES1 were custom produced by Rockland
Immunochemicals by immunizing with the KLH-conjugated peptide
C-RMKRPPKGNEILE, which encodes the enzyme’s C terminus.
IRS-1-associated PI3-kinase activity was analyzed as described pre-
viously (Wang and Summers, 2003). All other antibodies were from
Cell Signaling.
Statistical Analysis
Data are presented as means ± SEM. Statistical significance was de-
termined by Student’s t test when comparing two means or by one-
way analysis of variance (ANOVA) when comparing multiple means.
When statistical significance was detected by ANOVA, group differ-
ences were determined by Neuman-Keuls post hoc analyses. For glu-
cose and insulin tolerance tests, statistical comparisons were made
using the area under the curve. Analyses were performed using SAS/
STAT software (SAS Institute Inc.).
Supplemental Data
Supplemental Data include one table and seven figures and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/5/3/167/DC1/.
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